Hansa Biopharma AB (publ) reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported sales was SEK 15.4 million compared to SEK 3.83 million a year ago. Net loss was SEK 163.39 million compared to SEK 105.83 million a year ago.

Basic loss per share from continuing operations was SEK 3.67 compared to SEK 2.38 a year ago. Diluted loss per share from continuing operations was SEK 3.67 compared to SEK 2.38 a year ago.